查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858131

成人血红素血症检测市场按检测方式、疾病类型、最终用户和分销管道划分－全球预测，2025-2032年

Adult Hemoglobinopathy Testing Market by Modality, Disease Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，成人血红素血症检测市场规模将成长 81.4 亿美元，复合年增长率为 6.01%。

关键市场统计数据
基准年 2024 51亿美元
预计年份：2025年 54.1亿美元
预测年份 2032 81.4亿美元
复合年增长率 (%) 6.01%

确立加强成人血红蛋白血症检测在整个医疗服务体系和实验室网路中的临床和运作要务。

成人血红素血症检测处于临床需求与诊断创新交会点，影响临床医师如何检测、鑑别与管理成人族群中的遗传性血红素疾病。随着人们对镰状细胞疾病和地中海贫血等疾病终身影响的认识不断提高，临床医生和实验室主任都面临着对准确、及时且具有临床指导意义的诊断结果日益增长的期望。因此，诊断路径正从独立的确认性检测发展为多层次策略，整合表型检测、分子分析和标靶反射性方法，以优化患者照护并节省资源。

技术、临床指南和报销机制的不断发展变化正在重新定义成人血红蛋白血症检测的实施和评估方式。

成人血红蛋白血症检测格局正在转变，这主要得益于技术的成熟、医疗模式的改变以及支付方和监管机构优先事项的演变。分子方法（例如次世代定序和标靶基因分型）的进步使得血红素变异体和复杂地中海贫血基因型的识别更加精准，促使实验室从单一分析流程转向结合蛋白质和DNA检测方法的综合诊断演算法。同时，即时检测技术的改进正在分散初步筛检，并使患者能够更早获得医疗服务，尤其是在集中式检查室资源有限的地区。

2025年，不断变化的贸易措施将如何重塑血色素沉着症检测的诊断剂和设备采购、供应商策略以及成本动态？

2025年新关税的实施正在影响成人血红蛋白血症检测中使用的检查室耗材、诊断剂和照护现场设备的供应链、筹资策略和定价动态。由于关税增加了进口设备和试剂的到岸成本，检查室和医疗系统正在重新评估供应商合约和物流模式，以维持营运的连续性。为此，许多机构正在筹资策略多元化，寻求国内经销商，并协商基于采购量的合同，以缓解短期成本压力。这些转变可能会对采购计画和资本支出计画产生连锁反应，促使人们更加关注保质期更长的试剂和能够降低单次检测成本的整合工作流程设备。

基于跨模式、疾病亚型、最终用户和通路配置的细分，诊断和商业性意义

细緻的市场区隔方法能够明确哪些领域的应用最有可能加速，以及哪些领域的针对性产品开发能够带来最大的临床和商业性回报。根据检测方式，市场可分为实验室就地检验）。实验室检测又可细分为电泳、基因分析和高效液相层析），而就地检验包括专为分散式筛检设计的快速检测。这些检测方式的差异也体现在诊断流程中：检查室仍然依赖电泳和HPLC进行初步的蛋白质表征，但越来越多地将基因分析整合到确诊和困难病例的解决中。

区域诊断生态系统和采用梯度将决定全球市场中成人血红蛋白血症检测的优先顺序和部署方式。

区域动态对成人血红素血症检测的采纳模式、监管互动以及诊断生态系统的结构有显着影响。在美洲，临床基​​础设施和成熟的检查室网路促进了先进分子诊断技术和整合检测流程的快速普及，而支付方的多样性和区域报销政策则造就了异质性的商业性环境，临床效用的证明至关重要。因此，在医疗保健采购方要求明确疗效相关性的市场中，能够提供全面验证方案和可靠上市后证据的供应商往往能更快获得市场认可。

诊断公司为推动技术应用、保持差异化优势以及确保供应和监管方面的韧性而采取的竞争与合作策略

诊断公司之间的竞争动态正朝着将检测创新、服务交付和证据产生相结合的合作模式转变。领先企业正投资于整合蛋白质分离方法、分子检测和数位化报告的平台，使检查室能够简化工作流程，并为临床医生提供统一的诊断结果。与学术中心和临床网络建立策略伙伴关係正日益被用于产生真实世界证据、检验在不同患者群体中的效用，并加强医疗保险报销对话和临床指南的采纳。同时，一些机构正在推行垂直整合策略以控制试剂品质和伙伴关係连续性，而其他机构则强调通路合作，以扩大地域覆盖范围并提升客户支援。

製造商、实验室和医疗系统可以采取哪些切实可行的策略步骤来加速诊断技术的普及应用、确保诊断服务的可及性并管理营运风险

致力于影响临床实践并获取永续价值的产业领导者应采取一系列策略行动，将产品开发、临床证据和客户参与相结合。首先，透过投资模组化诊断解决方案来降低复杂性并提高诊断产量比率，使检查室能够在单一、可扩展的平台上整合基于蛋白质和基因的方法。其次，制定引人注目的价值主张和真实世界证据包，量化临床效用和后续效益，以便与支付方和医院采购委员会进行更有效的对话。第三，优先考虑供应链多元化和区域合作，以降低关税造成的成本波动，并确保试剂和设备的持续供应。

采用严谨的混合方法，结合技术检验、相关人员参与和监管分析，以获得可操作的诊断见解。

本分析的研究基础是将同行评审文献、监管文件和技术白皮书的全面审查与和临床及实验室专家的结构化访谈相结合，从而对诊断性能特征和临床效用进行三角验证。数据综合分析包括对检测原理、技术完备等级和已记录的临床工作流程的分析，并辅以对实验室主任、血红蛋白病临床医生和供应链经理的访谈，以获得营运方面的见解。在条件允许的情况下，分析准确性透过验证和能力验证结果进行评估，监管核准和指导文件则为合规要求提供了依据。

整合策略重点和临床需求，以确定诊断如何在成人血红素疾病治疗中发挥持续价值。

成人血红素血症检测正处于曲折点，技术能力、临床需求和经济压力都要求采用更整合、更具韧性且基于实证医学的诊断策略。实验室和医疗系统面临越来越大的挑战，需要在提供准确的基因型和表型资讯的同时，应对贸易和供应链动态动态带来的交付时间和成本压力。因此，成功实施这些策略需要协调临床工作流程和检测方法的选择，投资于实证医学研究以支持支付者和指南的采纳，并建立能够预见监管和关税变化的供应链策略。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 用于诊断成人血红蛋白疾病的次世代定序技术的进展
  • 整合人工智慧主导的数位显微镜解决方案，实现成人血红素病精准诊断
  • 利用微流体纸基分析仪扩大照护现场血色素沉着症检测规模
  • 扩大高通量质谱技术在成人血红素变异体全面分析的应用
  • 新兴的非侵入性产前筛检平台影响成人血红素病风险评估
  • 开发一种针对成人族群中罕见血红蛋白血症突变的多重PCR检测方法
  • 增加远距远端医疗支援的遗传咨询服务，以管理成人血红蛋白疾病
  • 监理核准对新型成人血红素病诊断试剂盒商业化的影响

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 成人血红素血症检测市场（依检测方式划分）

  • 实验室检测
    • 电泳
    • 基因分析
    • 高效液相层析
  • 就地检验
    • 快速检测

9. 成人血红素血症检测市场（依疾病类型划分）

  • 血红素C病
  • 镰状细胞性贫血症
  • 地中海型贫血
    • α地中海贫血
    • β-地中海型贫血
    • Delta贫血

第十章 成人血红素血症检测市场（依最终用户划分）

  • 诊断实验室
    • 医院检查室
    • 独立测试机构
    • 参考检验机构
  • 医院
    • 二级护理医院
    • 三级医院
  • 研究所

第十一章 成人血红素血症检测市场（依分销管道划分）

  • 直销
  • 经销商
    • 当地经销商
    • 区域经销商
  • 线上供应商

12. 成人血红素血症检测市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 成人血红素血症检测市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国成人血红素血症检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Roche Diagnostics International AG
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Abbott Laboratories
    • Bio-Rad Laboratories, Inc.
    • Ortho Clinical Diagnostics Inc.
    • Danaher Corporation
    • Becton, Dickinson and Company
    • PerkinElmer, Inc.
    • Sysmex Corporation
Product Code: MRR-C002B1C99763

The Adult Hemoglobinopathy Testing Market is projected to grow by USD 8.14 billion at a CAGR of 6.01% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.10 billion
Estimated Year [2025] USD 5.41 billion
Forecast Year [2032] USD 8.14 billion
CAGR (%) 6.01%

Establishing the clinical and operational imperative for enhanced adult hemoglobinopathy diagnostics across care continuums and laboratory networks

Adult hemoglobinopathy testing sits at the intersection of clinical necessity and diagnostic innovation, shaping how clinicians detect, characterize, and manage inherited hemoglobin disorders in adult populations. As awareness of lifelong implications of conditions such as sickle cell disease and thalassemia increases, clinicians and laboratory directors alike face rising expectations for accurate, timely, and clinically actionable diagnostic results. Consequently, diagnostic pathways have evolved from singular confirmatory assays to layered strategies that integrate phenotypic testing, molecular analysis, and targeted reflex approaches that optimize patient care while conserving resources.

In parallel, health systems are recalibrating screening and care pathways to support adults who may have transitioned from pediatric services or who have undiagnosed conditions presenting later in life. This realignment emphasizes longitudinal management, genotype-informed therapy selection, and surveillance for disease complications. Therefore, stakeholders including laboratory managers, hospital systems, payers, and device developers must align clinical workflows with technological capabilities to ensure diagnostic results translate into improved outcomes. With these dynamics in mind, the following analysis synthesizes the major inflection points reshaping testing strategies, the regulatory and economic headwinds that can influence procurement and access, and pragmatic segmentation and regional considerations to guide clinical and commercial decision-making.

Unfolding technological, clinical guideline, and reimbursement shifts that are redefining how adult hemoglobinopathy testing is delivered and valued

The landscape of adult hemoglobinopathy testing is undergoing transformative shifts driven by technological maturation, changing care models, and evolving payer and regulatory priorities. Advances in molecular methods such as next-generation sequencing and targeted genotyping have enabled more precise discrimination among hemoglobin variants and complex thalassemia genotypes, and as a result laboratories are transitioning from single-analyte workflows toward integrated diagnostic algorithms that combine protein-based and DNA-based modalities. At the same time, improved point-of-care technologies are decentralizing initial screening and enabling earlier linkage to care, particularly in settings where access to centralized laboratories is constrained.

Concurrently, clinical practice guidelines and specialty societies are placing greater emphasis on genotype-informed therapeutic decisions, which elevates the diagnostic test from a confirmatory role to a decision-making instrument. Automation, digital laboratory information systems, and connected diagnostics are facilitating higher throughput and faster turnaround times, while data interoperability initiatives are enabling longitudinal patient tracking across care settings. Moreover, payer scrutiny and value-based contracting are incentivizing diagnostics that demonstrably reduce avoidable morbidity and downstream costs, prompting vendors to focus on evidence generation and real-world outcome studies. Taken together, these forces are reshaping who performs testing, where testing occurs, and how diagnostic value is defined and measured.

How evolving trade measures in 2025 are reshaping procurement, supplier strategies, and cost dynamics for diagnostic reagents and devices in hemoglobinopathy testing

The introduction of new tariff measures in 2025 is influencing supply chains, procurement strategies, and pricing dynamics for laboratory consumables, diagnostic reagents, and point-of-care devices used in adult hemoglobinopathy testing. When tariffs increase the landed cost of imported instrumentation and reagents, laboratories and health systems reassess supplier agreements and logistics models to maintain operational continuity. In response, many organizations are diversifying sourcing strategies, seeking domestic distributors, and negotiating volume-based contracts to mitigate short-term cost pressures. These shifts create ripple effects across procurement timetables and capital expenditure planning, and they can heighten interest in reagents with longer shelf lives or equipment that offers consolidated workflows to reduce per-test cost exposure.

In addition, diagnostic manufacturers and distributors adjust commercial strategies to protect market access and margins. Some vendors accelerate localization efforts, including regional assembly or partnering with local distributors to reduce tariff exposure. Others shift toward service-based models that emphasize reagent rental, managed inventory, and bundled support agreements that smooth cost volatility for customers. From a clinical perspective, payers and hospital procurement committees scrutinize test utilization and may tighten approval pathways for higher-cost assays, increasing the onus on diagnostic developers to demonstrate comparative clinical utility. Overall, the cumulative impact of tariffs is prompting stakeholders to prioritize supply chain resilience, pricing transparency, and evidence-based justification for adopting next-generation diagnostic solutions.

Segmentation-driven diagnostic and commercial implications across modalities, disease subtypes, end users, and distribution channel configurations

A nuanced segmentation approach clarifies where adoption is most likely to accelerate and where targeted product development will generate the greatest clinical and commercial return. Based on modality, the market separates into laboratory based tests and point of care tests, with laboratory based testing further differentiated into electrophoresis, genetic analysis, and high performance liquid chromatography, while point of care testing encompasses rapid tests designed for decentralized screening. These modality distinctions inform diagnostic pathways: laboratories continue to rely on electrophoresis and HPLC for initial protein-based characterization but are increasingly integrating genetic analysis for definitive diagnosis and complex case resolution, whereas rapid point-of-care tests serve as first-line screens that expedite referral to centralized confirmatory testing.

When viewed by disease type, the segmentation highlights distinct needs across hemoglobin C disease, sickle cell disease, and thalassemia, with thalassemia itself requiring sub-classification into alpha thalassemia, beta thalassemia, and delta thalassemia to reflect diverse genetic and clinical consequences. These disease-driven differences affect assay design, sensitivity requirements, and counseling support services. The end user segmentation further clarifies operational and purchasing behaviors: diagnostic laboratories, which include hospital laboratories, independent laboratories, and reference laboratories, make decisions based on throughput, certification requirements, and interoperability needs; hospitals composed of secondary care hospitals and tertiary care hospitals prioritize rapid turnaround and integration with clinical decision support; and research institutes focus on assay flexibility and depth of genotypic information for investigational studies. Finally, distribution channels-direct sales, distributors organized into local and regional distributors, and online vendors-shape commercial pathways and after-sales support expectations, influencing how manufacturers prioritize channel investments and training programs.

Regional diagnostic ecosystems and adoption gradients that determine how adult hemoglobinopathy testing is prioritized and deployed across global markets

Regional dynamics materially influence adoption patterns, regulatory interactions, and the structure of diagnostic ecosystems in adult hemoglobinopathy testing. In the Americas, clinical infrastructure and established laboratory networks facilitate rapid adoption of advanced molecular diagnostics and integrated laboratory workflows, while payer diversity and regional reimbursement policies create a heterogeneous commercial landscape where demonstration of clinical utility is paramount. Consequently, vendors that provide comprehensive validation packages and robust post-market evidence tend to gain traction more quickly in markets where institutional purchasers demand clear outcome linkages.

Europe, Middle East & Africa present a mosaic of regulatory regimes and healthcare capabilities where centralized reference laboratories coexist with emerging point-of-care deployment in under-resourced settings. Regulatory harmonization efforts and collaborative public health initiatives in some countries are accelerating screening and confirmatory testing programs, yet supply chain variability and local procurement practices require tailored go-to-market strategies. In Asia-Pacific, high-volume testing environments, strong domestic manufacturing capacity, and rapid uptake of decentralized diagnostics are shaping a competitive arena characterized by price sensitivity and technological innovation. Governments and health systems in the region are also investing in newborn and adult screening programs, which increases demand for scalable platforms and flexible service models. Across all regions, scaling diagnostics successfully requires alignment with local clinical guidelines, robust training for laboratory personnel, and logistics strategies adapted to regional supply chain realities.

Competitive and collaborative strategies that diagnostic firms adopt to drive adoption, sustain differentiation, and ensure supply and regulatory resilience

Competitive dynamics among diagnostic companies are shifting toward collaborative models that combine assay innovation with service delivery and evidence generation. Leading firms are investing in platforms that integrate protein-based separation methods with molecular assays and digital reporting, enabling laboratories to streamline workflows and present unified diagnostic outputs to clinicians. Strategic partnerships with academic centers and clinical networks are increasingly used to generate real-world evidence and to validate utility across diverse patient cohorts, strengthening reimbursement dialogues and clinical guideline adoption. In parallel, some organizations pursue vertical integration strategies to control reagent quality and supply continuity, while others emphasize channel partnerships to improve geographic reach and customer support.

Innovation focus is broadly centered on assay sensitivity, ease of use, and connectivity. Diagnostic developers that demonstrate interoperability with laboratory information systems and electronic health records find it easier to embed testing into clinical pathways. Moreover, companies that offer comprehensive training, proficiency testing, and lifecycle support secure stronger long-term relationships with institutional customers. Importantly, agility in regulatory submissions and post-market surveillance enables faster market access in jurisdictions with evolving approval frameworks. Overall, the competitive environment rewards firms that combine technical excellence with pragmatic commercial models and demonstrable clinical impact.

Practical strategic steps that manufacturers, laboratories, and health systems can take to accelerate adoption, secure access, and manage operational risk in diagnostics

Industry leaders seeking to influence clinical practice and capture sustainable value should pursue a coordinated set of strategic actions that align product development, clinical evidence, and customer engagement. First, invest in modular diagnostic solutions that allow laboratories to combine protein-based and genetic approaches within a single, scalable platform, thereby reducing complexity and improving diagnostic yield. Second, develop compelling value dossiers and real-world evidence packages that quantify clinical utility and downstream benefits, enabling more effective conversations with payers and hospital procurement committees. Third, prioritize supply chain diversification and regional partnerships to mitigate tariff-driven cost volatility and to ensure continuity of reagent and instrument availability.

Additionally, strengthen go-to-market models by tailoring distribution strategies to end user needs; this means offering turnkey services and training for hospital laboratories, specialized support for reference laboratories, and simplified deployment kits for point-of-care settings. Engage proactively with regulatory authorities and clinical guideline bodies to align test indications and reporting standards, and invest in digital integration to support longitudinal patient management and outcome measurement. Finally, build cross-functional teams that include clinical affairs, health economics, and customer success to translate scientific advances into adoption-ready solutions. These measures will position organizations to respond to evolving clinical demands while maintaining commercial agility.

A rigorous mixed-methods approach combining technical validation, stakeholder engagement, and regulatory analysis to derive practical diagnostic insights

The research underpinning this analysis combined a comprehensive review of peer-reviewed literature, regulatory filings, and technical white papers with structured engagements of clinical and laboratory experts to triangulate diagnostic performance characteristics and clinical utility considerations. Data synthesis included analysis of assay principles, technology readiness levels, and documented clinical workflows, supplemented by interviews with laboratory directors, clinicians specializing in hemoglobinopathies, and supply chain managers to capture operational realities. Where available, validation studies and proficiency testing results informed assessments of analytic accuracy, while regulatory approvals and guidance documents provided context on compliance requirements.

To ensure robustness, findings were cross-validated against multiple independent sources and subjected to scenario analysis exploring varied procurement, tariff, and adoption pathways. Stakeholder feedback loops were used to refine interpretation of technical trade-offs and to prioritize recommendations that are both clinically meaningful and operationally feasible. Throughout the research process, emphasis was placed on transparency of assumptions, reproducibility of analytic steps, and alignment with current practice standards to ensure that conclusions are actionable for decision-makers across clinical, laboratory, and commercial functions.

Synthesis of strategic priorities and clinical imperatives that will determine how diagnostics deliver durable value in adult hemoglobinopathy care

Adult hemoglobinopathy testing is at an inflection point where technological capability, clinical expectations, and economic pressures converge to demand more integrated, resilient, and evidence-based diagnostic strategies. Laboratories and health systems are increasingly challenged to deliver precise genotypic and phenotypic information while managing turnaround times and cost pressures amplified by trade and supply-chain dynamics. Therefore, successful implementation requires harmonizing assay selection with clinical workflows, investing in evidence generation to support payer and guideline adoption, and building supply chain strategies that anticipate regulatory and tariff-induced disruptions.

Moving forward, stakeholders who adopt a systems perspective-aligning product design, distribution models, and clinical validation-will be better positioned to meet patient needs and to sustain commercial viability. Strategic investments in interoperability, training, and regional partnerships will yield dividends in adoption and continuity of care. Ultimately, the diagnostic community's collective ability to translate analytic advances into demonstrable clinical benefits will determine how adult hemoglobinopathy testing contributes to improved patient outcomes and more efficient care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advances in next-generation sequencing assays for adult hemoglobinopathy diagnostics
  • 5.2. Integration of AI-driven digital microscopy solutions for accurate adult hemoglobinopathy diagnosis
  • 5.3. Expansion of point-of-care hemoglobinopathy testing using microfluidic paper-based analytical devices
  • 5.4. Growing adoption of high-throughput mass spectrometry for comprehensive adult hemoglobin variant profiling
  • 5.5. Emergence of noninvasive prenatal screening platforms impacting adult hemoglobinopathy risk assessment
  • 5.6. Development of multiplex PCR assays targeting rare hemoglobinopathy mutations in adult populations
  • 5.7. Increase in telemedicine-enabled genetic counseling services for adult hemoglobinopathy management
  • 5.8. Impact of regulatory approvals on commercialization of novel adult hemoglobinopathy diagnostic kits

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Adult Hemoglobinopathy Testing Market, by Modality

  • 8.1. Laboratory Based Tests
    • 8.1.1. Electrophoresis
    • 8.1.2. Genetic Analysis
    • 8.1.3. High Performance Liquid Chromatography
  • 8.2. Point Of Care Tests
    • 8.2.1. Rapid Tests

9. Adult Hemoglobinopathy Testing Market, by Disease Type

  • 9.1. Hemoglobin C Disease
  • 9.2. Sickle Cell Disease
  • 9.3. Thalassemia
    • 9.3.1. Alpha Thalassemia
    • 9.3.2. Beta Thalassemia
    • 9.3.3. Delta Thalassemia

10. Adult Hemoglobinopathy Testing Market, by End User

  • 10.1. Diagnostic Laboratories
    • 10.1.1. Hospital Laboratories
    • 10.1.2. Independent Laboratories
    • 10.1.3. Reference Laboratories
  • 10.2. Hospitals
    • 10.2.1. Secondary Care Hospitals
    • 10.2.2. Tertiary Care Hospitals
  • 10.3. Research Institutes

11. Adult Hemoglobinopathy Testing Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors
    • 11.2.1. Local Distributors
    • 11.2.2. Regional Distributors
  • 11.3. Online Vendors

12. Adult Hemoglobinopathy Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Adult Hemoglobinopathy Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Adult Hemoglobinopathy Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Roche Diagnostics International AG
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Siemens Healthineers AG
    • 15.3.4. Abbott Laboratories
    • 15.3.5. Bio-Rad Laboratories, Inc.
    • 15.3.6. Ortho Clinical Diagnostics Inc.
    • 15.3.7. Danaher Corporation
    • 15.3.8. Becton, Dickinson and Company
    • 15.3.9. PerkinElmer, Inc.
    • 15.3.10. Sysmex Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ADULT HEMOGLOBINOPATHY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ELECTROPHORESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ELECTROPHORESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ELECTROPHORESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ELECTROPHORESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ELECTROPHORESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ELECTROPHORESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GENETIC ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GENETIC ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GENETIC ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GENETIC ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HEMOGLOBIN C DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HEMOGLOBIN C DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HEMOGLOBIN C DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HEMOGLOBIN C DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HEMOGLOBIN C DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HEMOGLOBIN C DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ALPHA THALASSEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ALPHA THALASSEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ALPHA THALASSEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ALPHA THALASSEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ALPHA THALASSEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ALPHA THALASSEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY BETA THALASSEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY BETA THALASSEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY BETA THALASSEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY BETA THALASSEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DELTA THALASSEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DELTA THALASSEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DELTA THALASSEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DELTA THALASSEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DELTA THALASSEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DELTA THALASSEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ONLINE VENDORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ONLINE VENDORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ONLINE VENDORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ONLINE VENDORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ONLINE VENDORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY ONLINE VENDORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTORS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORY BASED TESTS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY POINT OF CARE TESTS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ADULT HEMOGLOBI